Filing Flows › United Therapeutics (UTHR) › Capital expenditures
United Therapeutics (UTHR) capital expenditures by quarter
United Therapeutics' capital expenditures were $181M in Q3 2026 (third quarter 2026), +67% from Q2 2026. Over the last 7 quarters it ranged from $62.2M (Q2 2025) to $210M (Q3 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $181M | +67% | -14% |
| Q2 2026 | $108M | +7% | +74% |
| Q1 2026 | $101M | -42% | +35% |
| Q4 2025 | $173M | -18% | — |
| Q3 2025 | $210M | +238% | — |
| Q2 2025 | $62.2M | -17% | — |
| Q1 2025 | $74.9M | — | — |
Q3 2026 at a glance
United Therapeutics, Q3 2026: revenue $832M (+4% year over year), operating margin 37.0%, net earnings $259M, operating cash flow $306M. The chart follows the revenue to costs, profit and cash.
Questions
What is United Therapeutics' capital expenditures?
United Therapeutics' capital expenditures were $181M in Q3 2026 (third quarter 2026), +67% from Q2 2026.
How has United Therapeutics' capital expenditures changed?
Over the last 7 quarters it ranged from $62.2M (Q2 2025) to $210M (Q3 2025).